Futura Medical

FUM.LPhase 3

Guildford, United Kingdomfuturamedical.com

Futura Medical has transitioned from a pre-revenue R&D group to a commercial-stage company with its lead product, Eroxon®, now available in over 15 countries worldwide. The company's strategy focuses on addressing the large, underserved OTC sexual health market through innovative, topically delivered gel formulations, with a pipeline that includes Eroxon® Intense and a women's health product, WSD4000. By partnering with leading consumer healthcare giants for marketing and distribution, Futura aims to leverage their resources and expertise to drive sales, build brand awareness, and achieve sustained profitability.

Market Cap

$3.5M

Focus

Drug Delivery

FUM.L · Stock Price

USD 59.6611.43 (-16.08%)

Historical price data

AI Company Overview

Technology Platform

Patented, proprietary expertise in developing fast-acting, topically delivered gel formulations for sexual health conditions, designed specifically for over-the-counter (OTC) use.

Pipeline Snapshot

6 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Tadalafil 5mg (Male) + Tadalafil 5mg (Female)	Erectile Dysfunction	Phase 3
MED2005	Erectile Dysfunction	Phase 3
Glyceryl trinitrate + MED Placebo	Erectile Dysfunction	Phase 2
Ibuprofen + Diclofenac + Methyl-salicylate / Menthol + Placebo	Pain	Phase 1
MED2005 + Nitrostat 0.6Mg Sublingual Tablet + Nitro Pohl	Erectile Dysfunction	Phase 1

Funding History

Total raised: $20.5M

Grant$2MInnovate UKJun 15, 2018

IPO$12MUndisclosedMar 20, 2013

Series A$5MUndisclosedJun 15, 2005

Seed$1.5MUndisclosedJun 15, 2003

Opportunities

Significant growth opportunity lies in the continued geographic expansion of Eroxon® into new markets and deeper penetration in existing ones through partner marketing.

The development of Eroxon® Intense offers a product line extension to capture more of the ED market, while WSD4000 represents a pioneering entry into the large, underserved women's sexual health OTC segment.

Risk Factors

Key risks include dependence on commercial partners for sales success, regulatory hurdles for pipeline products, competition from established prescription ED drugs and potential new OTC entrants, and the challenge of driving consumer adoption of a novel topical treatment in a crowded market.

Competitive Landscape

Primary competition comes from prescription oral PDE5 inhibitors (Viagra, Cialis). Eroxon® differentiates through its OTC availability, topical application avoiding systemic side effects, and rapid 10-minute onset. Its partnerships with global consumer health leaders provide a scale advantage in marketing and distribution over potential smaller OTC rivals.